Global R&D Pipeline
My Favorite
Hot Targets:
PD-1
Back
Total number of drugs
690
Phase II and later clinical stages
12.9%
Involving companies
866
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab | Pembrolizumab | Monoclonal antibody | Neoplasms Immune System Diseases Infectious Diseases Digestive System Disorders Hemic and Lymphatic Diseases Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases Nervous System Diseases Cardiovascular Diseases Congenital Disorders Endocrinology and Metabolic Disease Mouth and Tooth Diseases Otorhinolaryngologic Diseases Eye Diseases | PD-1 inhibitors | Merck & Co., Inc. | MSD KK (Tokyo) Merck Sharp & Dohme BV MSD R&D (China) Co. Ltd. Merck Sharp & Dohme Corp. Merck Sharp & Dohme LLC Merck & Co., Inc. Merck Sharp & Dohme (Ireland) Ltd. MSD Pharmaceuticals Pvt Ltd. Cue Biopharma, Inc. Otsuka Pharmaceutical Development & Commercialization, Inc. MSD Korea Co., Ltd. Organon Healthcare GmbH Merck Sharp & Dohme (Australia) Pty Ltd. MSD Italia Srl MSD France SAS | Approved | Approved | United States China European Union Japan United Kingdom Canada Australia Iceland Liechtenstein Norway | 2014-09-04 | 2018-07-20 | Accelerated Approval（United States） Breakthrough Therapy（United States） Orphan Drug（Australia） Orphan Drug（United States） PRIME（European Union） Priority Review（Australia） Priority Review（China） Priority Review（United States） Conditional marketing approval（China） Orphan Drug（Japan） | - | - | - | - | Pembrolizumab | - | - | detail > | |
| Dostarlimab-gxly | Dostarlimab-gxly | Monoclonal antibody | Neoplasms Urogenital Diseases Nervous System Diseases Congenital Disorders Digestive System Disorders Endocrinology and Metabolic Disease Respiratory Diseases Other Diseases Eye Diseases Skin and Musculoskeletal Diseases Immune System Diseases Hemic and Lymphatic Diseases | PD-1 inhibitors | AnaptysBio, Inc. | Tesaro, Inc. GSK Plc GlaxoSmithKline Trading Services Ltd. GlaxoSmithKline (Ireland) Ltd. Apices Soluciones SL Lixte Biotechnology Holdings, Inc. AnaptysBio, Inc. GlaxoSmithKline Australia Pty Ltd. GlaxoSmithKline LLC GlaxoSmithKline Research & Development Ltd. GlaxoSmithKline, Inc. | Approved | Phase 3 | United States European Union Australia Iceland South Korea Liechtenstein Norway Singapore | 2021-04-21 | - | Accelerated Approval（United States） Breakthrough Therapy（United States） Fast Track（United States） Priority Review（Australia） Priority Review（United States） | - | - | - | - | Dostarlimab-gxly | - | - | detail > | |
| Tislelizumab | Tislelizumab | Monoclonal antibody | Neoplasms Immune System Diseases Digestive System Disorders Hemic and Lymphatic Diseases Mouth and Tooth Diseases Otorhinolaryngologic Diseases Respiratory Diseases Other Diseases Endocrinology and Metabolic Disease Eye Diseases Skin and Musculoskeletal Diseases Urogenital Diseases | PD-1 inhibitors | BeOne Medicines Ltd. | BeOne Medicines Ltd. Novartis AG BeiGene (Shanghai) Co. Ltd. BeiGene USA, Inc. BeiGene AUS Pty Ltd. Glenmark Pharmaceuticals Ltd. BeiGene (Suzhou) Co. Ltd. BeiGene Guangzhou Biologics Manufacturing Co. Ltd. BeiGene Ireland Ltd. Veracyte, Inc. BeiGene Pharmaceuticals (Guangzhou) Co. Ltd. Antengene Corp. Ltd. BeiGene Switzerland GmbH Boehringer Ingelheim Biopharmaceuticals (China) Ltd. RemeGen Co., Ltd. | Approved | Approved | United States China European Union Japan Australia India Israel Iceland Liechtenstein Norway | 2019-12-26 | 2019-12-26 | Orphan Drug（European Union） Orphan Drug（United States） Priority Review（China） Special Review Project（China） Conditional marketing approval（China） | - | - | - | - | Tislelizumab | - | - | detail > | |
| Camrelizumab | Camrelizumab | Monoclonal antibody | Neoplasms Immune System Diseases Digestive System Disorders Hemic and Lymphatic Diseases Mouth and Tooth Diseases Otorhinolaryngologic Diseases Respiratory Diseases Other Diseases Urogenital Diseases Skin and Musculoskeletal Diseases Endocrinology and Metabolic Disease | PD-1 inhibitors ADCC T lymphocytes stimulants | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | HUTCHMED (China) Ltd. Luzsana Biotechnology, Inc. CG Invites Co., Ltd. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Suzhou Suncadia Biopharmaceuticals Co., Ltd. Ruijin Hospital | Approved | Approved | China | 2019-05-29 | 2019-05-29 | Breakthrough Therapy（China） Orphan Drug（European Union） Orphan Drug（United States） Priority Review（China） Conditional marketing approval（China） | - | - | - | - | Camrelizumab | - | - | detail > | |
| Sintilimab | Sintilimab | Monoclonal antibody | Neoplasms Immune System Diseases Digestive System Disorders Hemic and Lymphatic Diseases Respiratory Diseases Urogenital Diseases Other Diseases Eye Diseases | PD-1 inhibitors | Eli Lilly & Co. Innovent Biologics (Suzhou) Co. Ltd. | Innovent Biologics (Suzhou) Co. Ltd. RemeGen Co., Ltd. Innovent Biologics, Inc. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. HUTCHMED (China) Ltd. The University of Texas MD Anderson Cancer Center Shenzhen Chipscreen Biosciences Co., Ltd. Laekna Therapeutics (Shanghai) Co., Ltd. Eli Lilly & Co. | Approved | Approved | China Macao | 2018-12-24 | 2018-12-24 | Breakthrough Therapy（China） Orphan Drug（European Union） Orphan Drug（United States） Priority Review（China） Special Review Project（China） Conditional marketing approval（China） | - | - | - | - | Sintilimab | - | - | detail > | |
| Toripalimab | Toripalimab | Monoclonal antibody | Neoplasms Digestive System Disorders Mouth and Tooth Diseases Otorhinolaryngologic Diseases Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases Immune System Diseases Hemic and Lymphatic Diseases Nervous System Diseases Congenital Disorders Endocrinology and Metabolic Disease | PD-1 inhibitors | Shanghai Junshi Biosciences Co., Ltd. | Shanghai Junshi Biosciences Co., Ltd. Shanghai Rxilient Biotechnology Co., Ltd Coherus Oncology, Inc. Topalliance Biosciences, Inc. Tmc Pharma (Eu Ltd. Cancer Hospital Chinese Academy of Medical Sciences Ascentage Pharma Group, Inc. Apotex, Inc. Dr. Reddy's Laboratories Ltd. | Approved | Approved | United States China European Union United Kingdom Canada Australia India United Arab Emirates Hong Kong Iceland Jordan Kuwait Liechtenstein Norway Pakistan Singapore | 2018-12-17 | 2018-12-17 | Breakthrough Therapy（United States） Fast Track（United States） Orphan Drug（Australia） Orphan Drug（European Union） Orphan Drug（United States） Priority Review（China） Priority Review（United States） Priority Review（Singapore） Conditional marketing approval（China） | - | - | - | - | Toripalimab | - | - | detail > | |
| Cemiplimab-RWLC | Cemiplimab-RWLC | Monoclonal antibody | Neoplasms Respiratory Diseases Urogenital Diseases Skin and Musculoskeletal Diseases Immune System Diseases Infectious Diseases Digestive System Disorders Endocrinology and Metabolic Disease Eye Diseases Hemic and Lymphatic Diseases Mouth and Tooth Diseases Other Diseases Nervous System Diseases | PD-1 inhibitors | Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. Sanofi-Aventis Recherche & Développement SA Sensei Biotherapeutics, Inc. EMD Serono Research & Development Institute, Inc. Sanofi Regeneron Ireland DAC Sanofi-Aventis Canada, Inc. Sanofi (China) Investment Co. Ltd. Sanofi BV Vyriad, Inc. Astellas Pharma, Inc. Immune-Onc Therapeutics, Inc. Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd. Sanofi-Aventis Australia Pty Ltd. Genzyme Corp. Sanofi KK | Approved | Phase 3 | United States European Union Japan United Kingdom Canada Australia Brazil Iceland Liechtenstein Norway | 2018-09-28 | - | Accelerated Approval（United States） Breakthrough Therapy（United States） Orphan Drug（Australia） Orphan Drug（United States） Paediatric investigation plan（European Union） Priority Review（United States） | - | - | - | - | Cemiplimab-RWLC | - | - | detail > | |
| IBI-363 | IBI-363 | Antibody fusion proteins | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Eye Diseases Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases Immune System Diseases Hemic and Lymphatic Diseases | IL2RA agonists PD-1 inhibitors | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Biologics (Suzhou) Co. Ltd. Fortvita Biologics (USA) Inc. | Phase 3 | Phase 3 | - | - | - | Breakthrough Therapy（China） Fast Track（United States） | - | - | - | - | IBI-363 | - | - | detail > | |
| Pembrolizumab/Hyaluronidase | Pembrolizumab/Hyaluronidase | Monoclonal antibody Enzyme | Neoplasms Infectious Diseases Digestive System Disorders Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases Immune System Diseases Eye Diseases Hemic and Lymphatic Diseases | Hyaluronic acid modulators PD-1 inhibitors | Merck Sharp & Dohme Corp. | Merck Sharp & Dohme LLC MSD R&D (China) Co. Ltd. Merck Sharp & Dohme BV Merck Sharp & Dohme Corp. BSP Pharmaceuticals SpA Merck & Co., Inc. | Approved | NDA/BLA | United States | 2025-09-19 | - | Priority Review（United States） Orphan Drug（Japan） | - | - | - | - | Pembrolizumab/Hyaluronidase | - | - | detail > | |
| Genolimzumab | Genolimzumab | Monoclonal antibody | Neoplasms Urogenital Diseases Immune System Diseases Hemic and Lymphatic Diseases Other Diseases Nervous System Diseases Digestive System Disorders Respiratory Diseases Skin and Musculoskeletal Diseases | PD-1 inhibitors | Zhejiang Crownmab Biotech Co. Ltd. | Genor Biopharma Co., Ltd. Zhejiang Crownmab Biotech Co. Ltd. | Phase 3 | Phase 2 | - | - | - | Priority Review（China） | - | - | - | - | Genolimzumab | - | - | detail > |
Total 690 data
1
2
3
4
5
6
...
68
69
